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Background: IL-33, a member of the IL-1 cytokine family, binds to heterodimeric receptors ST2 and
IL-1 receptor accessory protein, and activates Th2-type immune responses. The signals from the ST2
receptor are mediated by the two major pathways, including AP-1 and NF-kB molecules. The present
study examined whether IL-33 induced ICAM-1 expression in bone marrow-derived mast cells
(BMMCs).
Methods: BMMCs from C57BL/6J mice, cultured in media containing IL-3 (20 ng/ml), were treated with
IL-33 (50 ng/ml) for up to 72 h. ICAM-1 expression with mRNA and protein, degranulation of siRNA
ICAM-1 transfected BMMCs, and cell adhesion were analyzed. In the in vivo part of the experiment rIL-33
(500 ng) was injected intradermally into the ear pinnae of mice and any resulting pathological changes
were assessed.
Results: ICAM-1 mRNA expression was increased one hour after IL-33 stimulation while ICAM-1
protein attained maximum expression levels 24 h after IL-33 stimulation. Moreover, IL-33-treated
BMMCs showed increased cell adhesion to the LFA-1-coated plate. However, siRNA ICAM-1 trans-
fected BMMCs did not affect Ag/IgE-mediated degranulation level compared to the wild control siRNA.
Pre-treatment with a NF-kB inhibitor dramatically reduced ICAM-1 expression in IL-33-treated
BMMCs, suggesting the involvement of NF-kB in the process. In vivo study, at 6 h after IL-33 treat-
ment, MCs histologically showed up-regulated ICAM-1 expression though the number of tryptase-
positive cells did not change.
Conclusions: These data suggest that MCs increase ICAM-1 expression and activate LFA-1 positive cells in
the early phase of skin inﬂammation in response to IL-33.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Mast cells (MCs) are recognized as tissueeresident cells of he-
matopoietic origin, i.e., cells that develop in tissues like the skin and
mucosa. MCs participate in the innate and acquired immune re-
actions through the release of an array of inﬂammatory mediators
following receptor-dependent activation. These mediators, how-
ever, are also responsible for initiating the cellular and pathological
manifestations of allergic disorders including anaphylaxis, asthma,
rhinitis and atopic dermatitis.1,2 MCs are predominantly activated
through Ag/IgE-mediated aggregation of the high-afﬁnity IgE re-
ceptor (FcεRI). It is apparent that cytokines and other molecules
present in the surrounding milieu can amplify MC signaling and
responds to the antigen.gy, Tokyo Medical University,
Japan.
).
ety of Allergology.
rgology. Production and hosting by ElseIL-33 is a new member of the IL-1 cytokine family that binds to
heterodimeric receptors comprised of the ST2 and IL-1 receptor
accessory protein.3,4 IL-33, expressed in various cells such as ﬁ-
broblasts, keratinocytes and endothelial cells, is located in the nu-
cleus of cells in a steady state, and is released upon cell lysis
following pro-inﬂammatory stimulation.3,5 MCs also express ST2
receptors and demonstrated a strong response against Ag/IgE due
to IL-33.6
Intercellular adhesion molecule-1 (ICAM-1), immunoglobulin
supergene family of cellular adhesion molecules with a 76e114-
kDa molecular mass contains calcium-independent trans-
membrane glycoprotein.7 ICAM-1 expresses constitutively on the
surface of various cell types including ﬁbroblasts, leukocytes, ker-
atinocytes and endothelial cells, and has the ability to be up-
regulated in response to a number of inﬂammatory mediators.
Murine MCs expressed several adhesion molecules,8,9 although the
expression of integrins varied with culture conditions.10,11 More-
over, MCs reduced contact hypersensitivity in ICAM-1-deﬁcient
mice.12 In the present study we found that IL-33 induced ICAM-1vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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described the effect of ICAM-1 using IL-33-treated BMMCs on the
Ag-IgE mediated response and the function of cell adhesion, and
analyzed the relationship between the IL-33 signaling pathway and
the ICAM-1 gene expression. We further examined ICAM-1
expression in MCs from a pathological perspective using dermal
injections of recombinant IL-33 into mice ear.
Methods
Mice
C57BL/6J mice were purchased from The Jackson Laboratory®
(Bar Harbor, ME, USA). All experiments were performed in accor-
dance with the practices of the institutional science community
and the national guidelines for animal experimentation and
approved by The Institutional Animal Care and Use Committee
(IACUC) of Tokyo Medical University.
Cell culture
BMMCs were developed from bone marrow obtained from the
femurs of 6e10 week old C57BL/6J mice as described.13 Brieﬂy, the
cells were cultured for 4e6 weeks in RPMI1640medium containing
10% FBS, glutamine (4 mM), sodium pyruvate (1 mM), penicillin
(100 units/ml), streptomycin (100 mg/ml), non-essential amino
acids (Sigma®, St Louis, MO, USA), HEPES (25 mM), 2-
mercaptoethanol (50 mM), and mouse recombinant IL-3 (20 ng/
ml) (Peprotech®, Rocky Hill, NJ, USA). The cells were maintained at
37 C in a humidiﬁed incubator gassed with 95% air and 5% CO2. The
culture medium was changed twice a week. The purity of the cul-
tures, as assessed by toluidine blue staining,13 FcεRI expression and
KIT expression, was >99%.
Cell sensitization
The BMMCs were sensitized with mouse anti-DNP-IgE (clone
SPE-7 100 ng/ml Sigma®) overnight in a cytokine-free medium.
After sensitization, the cells were washed three times with HEPES
buffer (10 mM HEPES [pH 7.4], 137 mM NaCl, 2.7 mM KCl, 0.4 mM
Na2HPO4$7H2O, 5.6 mM glucose, 1.8 mM CaCl2$2H2O, 1.3 mM
MgSO4$7H2O) containing 0.04% BSA prior to the activation
experiments.
Degranulation
Degranulation was measured by the release of the granule
component, b-hexosaminidase (b-hex), into the supernatant as
described.14 Sensitized cells were aliquoted into individual wells of
a 96-well plate (3 104 cells/well, 100 ml ﬁnal volume) and allowed
to equilibrate to 37 C for 10 min. Cells were then stimulated with
DNP-HSA (0e10 ng/ml) for 30 min in the wells. The reactions were
terminated by centrifugation (1600 g for 5 min) at 4 C. The su-
pernatant was then assayed for b-hex content. The remaining cells
were lysed by adding 0.1% Triton X and the aliquots were similarly
assayed for b-hex content. Degranulation was calculated as the
percentage of total b-hex found in the supernatants following
challenge.
Flow cytometric analysis of surface expression
Following the blocking of Fcε receptors with 2.4G2 (BD Phar-
mingen®, Franklin Lakes, NJ, USA), the cells were stained with APC-
anti FcεRI (eBioscience®, San Diego, CA, USA), PE-Anti-c-Kit (BD
Pharmingen®), FITC-anti ICAM-1 (eBioscience®), and 7-AminoActinomycin D (eBioscience®) to examine the expression of c-kit,
FcεRI, ICAM-1 and 7-AAD respectively. The cells were then incu-
bated for one hour at 4 C. After washing with phosphate buffered
saline (PBS), cells stained with Abwere analyzed using a FACS VACS
ﬂow cytometer (BD Biosciences®) and associated FLOWJO (Tree Star
Inc®, Ashland, OR, USA). MoFlo®High-Performance Cell Sorter
(Beckman Coulter®, Brea, CA, USA) was used to isolate FcεRI and c-
kit positive mast cells.
Gene expression analysis
Total RNAwas isolated using High Pure RNA Isolate Kit (Roche®,
Basel, Switzerland). Total RNA (0.5 mg) was used for reverse tran-
scription with a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems®, Waltham, MA, USA) in a 20-ml reaction tube.
One ml of the resulting cDNA was used for real-time PCR using the
primer andprobe formurine ICAM-F: 50-CCCACGCTACCTCTGCTC-30,
ICAM-R 50-GATGGATACCTGAGCATCACC-3 LFA-1-F 50-CCCAGTGT-
GAGTGTCAGTGC-30, LFA-1-R 50-TCCCAATGTAGCCAGACTCA-30
(Roche®). Gene expressionwas assessed by comparing the CT values
for the gene of interest and 18S rRNAwith themeanCT values for the
control group to determine a fold induction value, as previously
described.15,16
The transfection of siRNA ICAM-1 to BMMCs
BMMCs were treated with siRNA directed against ICAM-1 (sc-
44266, Santa Cruz®, Santa Cruz, CA, USA), or non-targeting control
siRNA (sc-37007, Santa Cruz®), both at 100 pmol. The siRNA was
transfected into 1  107 cells/sample with NEPA 21 Super Electro-
porator System (Nepa Gene®, Chiba, Japan) according to the man-
ufacturer's instructions. After transfection for 2 days, the BMMCs
were examined for degranulation and subjected to ﬂow cytometric
analysis.
Cell adhesion assay
To analyze cell adhesion with IL-33-treated BMMCs, 10 mg/ml
mouse LFA-1 (Sigma®) in PBS was coated onto 96-well Maxisorp
plates (Nunc, Rochester®, Rochester, NY, USA) at 4 C overnight.
BMMCs (1  106 cell/ml) were incubated with 3 mg/ml of calcein-
AM (Invitrogen-Molecular Probes®, Eugene, OR, USA) at 37 C for
20 min. After washing twice, the re-suspended cells were added to
0.03% BSA RPMI medium, coated into 96-well plates, and incu-
bated at 37 C for 1.5 h. Fluorescence was measured both before
and after washing the plates using a ﬂuorescence plate reader at
an excitation wavelength at 485 nm and emission wavelength
at 520 nm.
Hematoxylin and eosin, toluidine blue and immunoﬂuorescence
staining
Mouse rIL-33 (500 ng in 20 ml PBS, Peprotech®), or PBS was
injected intradermally into the left ear pinna of mice (insulin sy-
ringe, 29-guage, Terumo®, Tokyo, Japan). At 6 and 24 h, the
injected ears were harvested and ﬁxed by formalin. Sections of
skin tissue (4 mm) were deparafﬁnized and rehydrated. The he-
matoxylin and eosin (HE) and toluidine blue staining (pH 4.0) was
performed as described in the previous report.14 The samples were
ﬁrst treated with 0.5% hydrogen peroxidase/methanol, then sub-
jected to heat retrieval in 0.5 M citrate buffer (pH 6.0), and ﬁnally
treated with protein block Serum-Free Ready-To-Use (DAKO®,
Glostrup, Denmark) for one hour at room temperature. Tissue
sections were stained with anti-tryptase (Abcam®, Cambridge,
UK), anti ICAM-1 (Abcam®) overnight at 4 C. Next, they were
T. Numata et al. / Allergology International 65 (2016) 158e165160stained with Alexa Fluor 488 anti-rat IgG (Santa Cruz Biotech-
nology®, Santa Cruz, CA) and Alexa Fluor 549 anti-rabbit IgG
(Santa Cruz Biotechnology®) for 30 min at room temperature. The
nuclei were then stained with DAPI (eBioscience®), the cells andFig. 1. IL-33 induced ICAM-1 expression in BMMCs. ICAM-1 mRNA was measured by real-tim
of the expression level of ICAM-1 in IL-33-stimulated BMMCs. Shaded histograms: rat IgG
express ICAM-1 protein in BMMCs. (c) was representative of three independent experimenthe tissue were washed with PBS, and the samples were analyzed
using confocal laser microscopy (LSM 5 PASCAL, Carl Zeiss®,
Oberkochen, Germany) in conjunction with LSM image Brower
software (Carl Zeiss®).e PCR. (a) ICAM-1, (b) LFA-1, in IgEþ c-kitþ sorted BMMCs. (c) Flow cytometric analysis
2b; unshaded histograms: anti-ICAM-1 antibody. (d) Dose of IL-33 concentrations to
ts. Data represent mean and the SEM [(a,b,d) n ¼ 3]. *p < 0.05, **p < 0.01, t-test.
Fig. 2. IL-33 induced down regulation of ICAM-1 expression in ICAM-1 siRNA transfected BMMCs. siRNA (100 pmol) directed against ICAM-1 and non-targeting control siRNA were
transfected by electroporator system. Transfected BMMCs were stimulated with/without IL-33 (50 ng/ml) for 24 h. (a) Flow cytometric analysis of the expression level of ICAM-1
treated with IL-33. Shaded histograms: rat IgG2b; unshaded histograms: anti-ICAM-1 antibody. (b) The cells were then nonstarved of cytokines overnight and concurrently
sensitized with IgE. The cells were challenged with the indicated concentrations of Ag (DNP-HSA) for 30 min, and degranulation (b-hex) was determined. (a) was representative of
three independent experiments. Data represent mean and the SEM [(b) n ¼ 4]. **p < 0.01, t-test.
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Fig. 3. NF-kB was involved in up-regulation of ICAM-1 expression by IL-33 treatment.
JNK inhibitor: SP600125 (Sigma Aldrich®) 10 mM or NF-kB sigma® inhibitor: IKK In-
hibitor VII (Calbiochem®, Darmstadt, Germany) 2 mM were pre-treated with either of
the two reagents for 48 h and then the cells were stimulated with IL-33 (50 ng/ml) for
24 h. Percentage of inhibition of ICAM-1 expression was shown. IL-33-treated BMMCs
were set as the maximum control (100%). Data represent mean and the SEM. **p < 0.01,
t-test.
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Data are presented as the mean ± S.E. A two-tailed Student's
t-test was used for statistical analysis. When p values were p < 0.05,
the differences were considered to be signiﬁcant.
Results
IL-33 induced ICAM-1 mRNA and protein in BMMCs
BMMCs were cultured in media containing IL-3 (20 ng/ml) for
up to 6 weeks. Mature cultured BMMCs (4 weeks) expressed 99% of
the FcεRI and c-kit positive (data not shown). These were then
stimulated with IL-33 (50 ng/ml) for up to 72 h. The levels of ICAM-Fig. 4. IL-33-treated BMMCs showed increased cell adhesion to the LFA-1-coated plate. (a
coated with 10 mg/ml LFA-1 for 1.5 h. The upper panel shows the un-treated BMMCs and th
cells was assessed as described in Methods. Data represent mean and the SEM [n ¼ 3]. Th1 mRNA were analyzed from 0 to 24 h by FcεRIþ c-kitþ gated pure
MCs using the cell sorter system. Although the MCs slightly
expressed ICAM-1 without IL-33 stimulation, ICAM-1 mRNA
expression increased one hour after IL-33 stimulation (Fig. 1a). The
mRNA levels of ICAM-1 ligand (LFA-1; Fig. 1b), E-cadherin and
VCAM-1 were unaffected by IL-33 treatment (data not shown).
ICAM-1 protein expression increased at 24 h after IL-33 stimulation
in FcεRIþ c-kitþ sorted BMMCs. ICAM-1 expression remained high
after 48 and 72 h (Fig. 1c). An analysis of various IL-33 concentra-
tions showed that ICAM-1 was expressed at the minimal stimula-
tory concentration of 10 ng/ml. However, the quantity of IL-33
necessary for stimulation was found to be independent of ICAM-1
expression (Fig. 1d). Due to the absence of toxic effects, the rela-
tively high concentration of 50 ng/m of recombinant IL-33was used
in our experiments.IL-33 induced down regulation of ICAM-1 expression in ICAM-1
siRNA transfected BMMCs
In previous reports, it was observed that short period of IL-33
exposure enhanced Ag/IgE-mediated degranulation and cytokine
production in MCs.6,17e20 Prolonged exposure to IL-33 during the
development of mast cells down-regulated degranulation in MCs
which were cultured from CD34þ human peripheral blood and
BMMCs.21 In our data, BMMCs treated with IL-33 for 24 h showed
upregulated Ag/IgE-mediated degranulation compared with non-
treated BMMCs (Fig. 2b). To determine whether ICAM-1 inﬂu-
enced an Ag/IgE-mediated reaction in the MCs, ICAM-1 siRNA was
transfected into BMMCs using electroporation. As shown in Fig. 2a,
IL-33 treatment induced the down-regulation of ICAM-1 expres-
sion in ICAM-1 siRNA transfected BMMCs. In terms of degranula-
tion, there was no difference between ICAM-1 siRNA transfected
BMMCs and control siRNA transfected BMMCs (Fig. 2b). The data
from the analysis of ICAM-1 siRNA transfection demonstrated that
ICAM-1 induced by the IL-33 exposure did not affect the Ag/IgE-
mediated response.) BMMCs were stimulated with 50 ng/ml IL-33 for 24 h, and transferred to the plates
e lower panel shows IL-33-treated BMMCs. (b) The percentage of LFA-1-adherent mast
e experiments were repeated three times. **p < 0.01, t-test.
Fig. 5. IL-33 stimulated ICAM-1 expression in the mice skin. rIL-33 (500 ng in 20 ml PBS) was injected intradermally to ear pinna, and tissues were harvested at 6 and 24 h after
treatment and ﬁxed by formalin. (a) Hematoxylin Eosin stain, (b) Toluidine blue stain (c) stained with anti-tryptase, (d) anti-ICAM-1 and (e)merge were analyzed by confocal laser
microscopy. (f) Percentage (%) of ICAM-1 positive MCs (ICAM-1 positive mast cells/Total mast cells/focus) after 6 h IL-33 injection. (a)e(f) were representative of three experiments.
**p < 0.01, t-test.
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treatment
In our study, themast cells were shown to express ICAM-1 by IL-
33 treatment. Regarding IL-33 signaling, the ST2 receptor contains
the IL-1/IL-18 receptor in which IL-1 receptor-associated kinase
(IRAK) and TNF receptor-associated factor 6 (TRAF6) are involved.22
The engagement of TRAF6 leads to the activation of two key tran-
scription factors, which indicate the AP-1 pathway through the
JNK and NF-kB pathway.6 To identify factors associated with up-
regulated ICAM-1 expression within the ST2 signal pathway, JNK
inhibitor or NF-kB inhibitor was pre-treated with the BMMCs, and
ICAM-1 expression was analyzed 24 h after stimulation with IL-33
(50 ng/ml). NF-kB inhibitor-treated BMMCs showed dramatically
reduced ICAM-1 expression, whereas JNK inhibitor-treated BMMCs
showed slightly decreased ICAM-1 expression even in the repeated
experiments (Fig. 3). These data suggest that NF-kB regulates ICAM-
1 expression in IL-33-treated BMMCs.
IL-33-treated BMMCs showed increased cell adhesion to the LFA-1-
coated plate
In the cell adhesion assay, the un-treated BMMCs did not adhere
to the LFA-1-coated plate whereas the IL-33-treated BMMCs did so
at a rate 2.5 times greater than the former (Fig. 4 a, b).
IL-33 stimulated ICAM-1 expression in the mouse skin
In order to conﬁrm the association of IL-33 and ICAM-1 in vivo,
the ear pinnae were injected intradermally with rIL-33 and
observed at 6 and 24 h. The sliced skin sections, stained with HE
and toluidine blue (pH 4.0), were observed by microscopy.
Following IL-33 treatment for 6 h, the skin tissues showed a slight
increase in inﬁltrated cells compared with PBS-treated skin tissue
(Fig. 5a). MCs stained with toluidine blue did not increase during
the 6 h observation (Fig. 5b). The number of tryptase-positive cells
also showed no increase in either the IL-33-treated or the PBS-
treated cells (Fig. 5c). As shown in Fig. 5e, tryptase and ICAM-1
double positive cells were observed by confocal laser microscopy.
90% of ICAM-1 positive expression MCs were increased in the
murine dermis, compared with PBS-treated mice (Fig. 5f). These
data suggest that ICAM-1 is induced by IL-33 treatment at 6 h after
treatment in vivo study.
Discussion
IL-33 activates Th2-type immune responses with the enhance-
ment of IL-4, IL-5, and IL-13, and promotes the degranulation,
maturation, and production of pro-inﬂammatory cytokines in MCs
and eosinophils.3,17 IL-33 levels are elevated in the serum or various
tissues in atopic dermatitis, chronic asthma,5,23 and allergic
rhinitis24e26 as corroborated by reports that IL-33 activates
MCs.6,19,27,28 IL-33 stimulation leads to an increase in degranulation
and cell count of MCs.6,18,19,29
In search of various effects of IL-33 on BMMCs, we found for the
ﬁrst time that prolonged exposure of IL-33 stimulated both mRNA
and protein levels of ICAM-1. In order to clarify the physiological
role of upregulated ICAM-1 expression, we performed adhesion
assays using LFA-1-coated plate. As shown in Fig. 4, IL-33-treated
BMMCs showed signiﬁcantly increased cell adhesion to the LFA-
1-coated plate. In addition, IL-33 treatment for 24 h showed
increased Ag/IgE-mediated degranulation from BMMCs (Fig. 2b).
However, siRNA ICAM-1 transfected BMMCs did not affect Ag/IgE-
mediated degranulation level compared to the wild control siRNA(Fig. 2b) suggesting that ICAM-1 was not involved in degranulation
process.
Concerning the phenomena observed in these experiments, it
is uncertain why high dose and longtime exposure of IL-33 is
necessary for up-regulation of ICAM-1 expression. Recently we
have shown that IL-33 promotes MHC class II expression in
BMMCs,14 in which similar experimental conditions were neces-
sary. We excluded indirect effects by other secondary up-regulated
molecules by exchanging culture medium daily and by analyzing
expressions of various other candidate molecules. Therefore, we
think that up-regulation of ICAM-1 expression by IL-33 is a direct
effect of IL-33 though the precise mechanism of activation is not
unveiled.
Regarding IL-33 signaling, ST2 has two major pathways, namely
the AP-1 and NF-kB pathways. ICAM-1 promoter is reportedly
regulated by NF-kB and AP-1.29 In our data, NF-kB inhibitor
dramatically suppressed the ICAM-1 expression in the presence of
IL-33 (Fig. 3). We suggest that IL-33 activates NF-kB signaling and
lead to the MCs to secrete ICAM-1 via IL-33 regulation.
To verify the effect of IL-33 on ICAM-1 in vivo MCs, rIL-33 was
injected intradermally to the ear pinnas of mice. At 6 h after IL-33
treatment, MCs histologically showed up-regulated ICAM-1
expression though the number of tryptase-positive cells did not
change (Fig. 5). Taken together with the result of adhesion assay, IL-
33 promotes ICAM-1 expression in vivo and in vitro. However, up-
regulated ICAM-1 expression in MCs was not correlated with
accumulation of MCs or degranulation from BMMCs.
Previous reports have shown that the interaction between
ICAM-1 on MCs and the LFA-1 on activated T cells strengthened the
activation of the MCs.30 Further, Otsuka et al. have reported that
ICAM-1/LFA-1 interaction between MCs and DCs was essential for
the maturation and chemotactic activation of DCs as well as
strengthening contact hypersensitivity via ICAM-1 mediation.31
Based on these reports as well as our own ﬁndings, MCs can be
seen as expressing ICAM-1 after IL-33 stimulation has activated
LFA-1 positive cells in the early phase of inﬂammation. These
ﬁndings constitute a new approach to understanding the rela-
tionship between MCs and ICAM-1. ICAM-1 positive MCs that have
been induced by IL-33 will contribute to clarifying the patho-
physiology of skin inﬂammation.Acknowledgments
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